Close



Dec 9, 2023 08:30AM
Dec 5, 2023 07:30AM
Nov 7, 2023 07:30AM
Sep 13, 2023 07:31AM
Sep 13, 2023 07:30AM
Aug 2, 2023 04:05PM
Jun 2, 2023 07:34AM Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic C
May 9, 2023 07:31AM
May 9, 2023 07:30AM
Apr 12, 2023 07:31AM
Apr 12, 2023 07:30AM
Apr 12, 2023 07:30AM
Dec 10, 2022 10:00AM
Dec 10, 2022 10:00AM Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
Dec 5, 2022 07:30AM
Dec 5, 2022 07:30AM
Dec 1, 2022 07:30AM
Oct 11, 2022 08:05AM
Oct 11, 2022 08:05AM
Oct 11, 2022 08:05AM
Jul 28, 2022 07:30AM Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma
Jul 28, 2022 07:30AM
Jun 15, 2022 07:30AM
Jun 15, 2022 07:30AM
Jun 15, 2022 07:30AM
Jun 2, 2022 04:10PM
Jun 2, 2022 04:10PM
Mar 9, 2022 07:00AM Adaptive Biotechnologies (ADPT) Appoints Tycho Peterson as CFO
Mar 9, 2022 07:00AM
Mar 9, 2022 07:00AM
Feb 18, 2022 11:35AM
Feb 18, 2022 11:35AM
Feb 18, 2022 11:35AM
Feb 15, 2022 04:05PM
Feb 15, 2022 04:05PM Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
Dec 13, 2021 04:08PM
Dec 13, 2021 04:05PM
Dec 13, 2021 04:05PM
Dec 2, 2021 08:00AM
Dec 2, 2021 08:00AM
Nov 12, 2021 05:32AM
Nov 11, 2021 05:52PM Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients
Nov 11, 2021 05:52PM
Oct 4, 2021 05:51AM
Oct 2, 2021 01:15PM
Oct 2, 2021 01:15PM
Sep 30, 2021 07:30AM
Sep 30, 2021 07:30AM
Sep 16, 2021 08:04AM Adaptive Biotechnologies (ADPT) Will Present New SARS-CoV-2 Data from its Immune Medicine Platform at IDWeek 2021
Sep 16, 2021 08:03AM

251,728 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All